Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hemophilia B HELP
Based on 1,344 articles published since 2008
||||

These are the 1344 published articles about Hemophilia B that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. 2017

Iorio, A / Blanchette, V / Blatny, J / Collins, P / Fischer, K / Neufeld, E. ·Department of Health Research, Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. · Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Division of Hematology/Oncology, Hospital for Sick Children and Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada. · Department of Pediatric Hematology, University Hospital Brno, Brno, Czech Republic. · Arthur Bloom Haemophilia Centre, School of Medicine, University Hospital of Wales, Cardiff University, Cardiff, UK. · Van Creveldkliniek, University Medical Center, Utrecht, the Netherlands. · St Jude Children's Research Hospital, Memphis, TN, USA. ·J Thromb Haemost · Pubmed #29119666.

ABSTRACT: -- No abstract --

2 Guideline The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. 2016

Collins, P / Chalmers, E / Chowdary, P / Keeling, D / Mathias, M / O'Donnell, J / Pasi, K J / Rangarajan, S / Thomas, A. ·Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, UK. · Haemophilia Centre, Royal Hospital for Sick Children, Glasgow, UK. · Katharine Dormandy Haemophilia Centre, Royal Free Hospital, London, UK. · Haemophilia Centre, Churchill Hospital, Oxford, UK. · Haemophilia Centre, Great Ormond Street Hospital, London, UK. · Haemophilia Centre, St. James Hospital, Dublin, Ireland. · Haemophilia Centre, Royal London Hospital, London, UK. · Haemophilia Centre, Basingstoke and North Hampshire Hospital, Basingstoke, UK. · Haemophilia Centre, Royal Infirmary of Edinburgh, Edinburgh, UK. ·Haemophilia · Pubmed #27311929.

ABSTRACT: Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.

3 Guideline Definitions in hemophilia: communication from the SSC of the ISTH. 2014

Blanchette, V S / Key, N S / Ljung, L R / Manco-Johnson, M J / van den Berg, H M / Srivastava, A / Anonymous2650801. ·Pediatric Thrombosis and Hemostasis Program, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, ON, Canada. ·J Thromb Haemost · Pubmed #25059285.

ABSTRACT: -- No abstract --

4 Guideline Towards standardization of clot waveform analysis and recommendations for its clinical applications. 2013

Shima, M / Thachil, J / Nair, S C / Srivastava, A / Anonymous4430757. ·Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. mshima@naramed-u.ac.jp ·J Thromb Haemost · Pubmed #23648068.

ABSTRACT: -- No abstract --

5 Guideline Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. 2013

Collins, Peter W / Chalmers, Elizabeth / Hart, Daniel P / Liesner, Ri / Rangarajan, Savita / Talks, Kate / Williams, Mike / Hay, Charles R / Anonymous2260742. ·School of Medicine, Cardiff University, University Hospital of Wales, Wales, UK. ·Br J Haematol · Pubmed #23157203.

ABSTRACT: -- No abstract --

6 Guideline How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. 2012

Brown, S A / Barnes, C / Curtin, J / Dunkley, S / Ockelford, P / Phillips, J / Rowell, J / Smith, M / Tran, H / Anonymous2280742. ·Department of Haematology and Oncology, Royal Children's Hospital, Brisbane, Queensland, Australia. simon_brown@health.qld.gov.au ·Intern Med J · Pubmed #23157518.

ABSTRACT: The management of bleeds in patients with haemophilia A or B complicated by inhibitors is complex. Recombinant activated Factor VII (rFVIIa; NovoSeven RT) is an established therapy in these patients. To develop a consensus-based guide on the practical usage of rFVIIa in haemophilia complicated by inhibitors, nine expert haemophilia specialists from Australia and New Zealand developed practice points on the usage of rFVIIa, based on their experience and supported by published data. Practice points were developed for 13 key topics: control of acute bleeding; prophylaxis; surgical prophylaxis; control of breakthrough bleeding during surgery or treatment of acute bleeds; paediatric use; use in elderly; intracranial haemorrhage; immune tolerance induction; difficult bleeds; clinical monitoring of therapy; laboratory monitoring of therapy; concomitant antifibrinolytic medication; practical dosing. Access to home therapy with rFVIIa is important in allowing patients to administer treatment early in bleed management. In adults, 90-120 μg/kg is the favoured starting dose in most settings. Initial dosing using 90-180 μg/kg is recommended for children due to the effect of age on the pharmacokinetics of rFVIIa. In the management of acute bleeds, 2-hourly dosing is appropriate until bleeding is controlled, with concomitant antifibrinolytic medication unless contraindicated. The practice points provide guidance on the usage of rFVIIa for all clinicians involved in the management of haemophilia complicated by inhibitors.

7 Guideline In-hospital rehabilitation after multiple joint procedures of the lower extremities in haemophilia patients: clinical guidelines for physical therapists. 2011

De Kleijn, P / Fischer, K / Vogely, H Ch / Hendriks, C / Lindeman, E. ·Department of Rehabilitation, UMCU, Utrecht Van Creveldkliniek, Utrecht, The Netherlands. p.dekleijn@umcutrecht.nl ·Haemophilia · Pubmed #21457409.

ABSTRACT: This project aimed to develop guidelines for use during in-hospital rehabilitation after combinations of multiple joint procedures (MJP) of the lower extremities in persons with haemophilia (PWH). MJP are defined as surgical procedures on the ankles, knees and hips, performed in any combination, staged, or during a single session. MJP that we studied included total knee arthroplasty, total hip arthroplasty and ankle arthrodesis. Literature on rheumatoid arthritis demonstrated promising functional results, fewer hospitalization days and days lost from work. However, the complication rate is higher and rehabilitation needs optimal conditions. Since 1995, at the Van Creveldkliniek, 54 PWH have undergone MJP. During the rehabilitation in our hospital performed by experienced physical therapists, regular guidelines seemed useless. Guidelines will guarantee an optimal physical recovery and maximum benefit from this enormous investment. This will lead to an optimal functional capability and optimal quality of life for this elderly group of PWH. There are no existing guidelines for MJP, in haemophilia, revealed through a review of the literature. Therefore, a working group was formed to develop and implement such guidelines and the procedure is explained. The total group of PWH who underwent MJP is described, subdivided into combinations of joints. For these subgroups, the number of days in hospital, complications and profile at discharge, as well as a guideline on the clinical rehabilitation, are given. It contains a general part and a part for each specific subgroup.

8 Guideline [French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy]. 2009

Meunier, S / Trossaërt, M / Berger, C / Borel-Derlon, A / Dirat, G / Donadel-Claeyssens, S / Assolant, A Durin / Guérois, C / Lutz, P / Rafowicz, A / Rothschild, C / Chambost, H / Anonymous5310644. ·Unité d'Hémostase Clinique, Groupement Hospitalier Edouard-Herriot, CRMH, Centre Régional de Traitement de l'Hémophilie, Hôpital Edouard-Herriot, CHRU, Place d'Arsonval, 69437 Lyon 03, France. sandrine.meunier@chu-lyon.fr ·Arch Pediatr · Pubmed #19960603.

ABSTRACT: During the last decades, long-term prophylaxis has become the gold standard for the treatment of children with severe haemophilia A or B. Prophylactic replacement regimens modify the natural history of the disease by aiming at the prevention of haemarthrosis, target joints and arthropathy. This treatment represents a constraint and an enhanced exposure to anti-haemophilic concentrates, which means potential increase of related risks and significant additional cost. The context of crisis of confidence due to the blood borne infections in the 1980s, may have delayed prophylaxis as an universal gold standard.In the early 2000s, the French group CoMETH proposed recommendations based on the review of the international experience. At first, specific guidelines of long-term prophylaxis were dedicated to children with severe haemophilia A or B, aged 3 years or less, with no history of target joint or arthropathy. The main concerns of this regimen consist in the early start and the escalating intensification of the treatment. In the French haemophilia care centres, the diffusion of these guidelines has apparently induced a significant turning point in therapeutic practices for haemophilia children. In 2006, more comprehensive recommendations were diffused to take into account all the children with severe haemophilia, whatever the bleeding history and joint status. The analysis of their impact, jointly with the National cohort "France Coag Network", will first assess the widespread implementation of the recommendations and the observance of the prophylactic regimen and identify factors associated to the compliance.

9 Guideline Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. 2008

Keeling, D / Tait, C / Makris, M. ·Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford. ·Haemophilia · Pubmed #18422612.

ABSTRACT: Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines.

10 Editorial A golden age for Haemophilia treatment? 2018

Makris, M / Hermans, C. ·Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK. · Department of Immunity, Inflammation and Cardiovascular Disease, University of Sheffield, Sheffield, UK. · Haemostasis and Thrombosis Unit, Haemophilia Clinic, Division of Haematology, St-Luc University Hospital, Catholic university of Louvain, Brussels, Belgium. ·Haemophilia · Pubmed #29601683.

ABSTRACT: -- No abstract --

11 Editorial Non-replacement therapy for haemophilia treatment: fetching the east by the west. 2018

Marietta, Marco / Luppi, Mario. ·Haematology Unit, Azienda Ospedaliero-Universitaria di Modena, Italy · Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy ·Blood Transfus · Pubmed #29517963.

ABSTRACT: -- No abstract --

12 Editorial Biosimilars and haemophilia. 2018

Thomas, A E. ·Clinical Trials, Biologicals and Vaccines Expert Advisory Group, Commission on Human Medicines, London, UK. ·Haemophilia · Pubmed #29341406.

ABSTRACT: -- No abstract --

13 Editorial Haemophilia B is clinically less severe than haemophilia A: further evidence. 2018

Franchini, Massimo / Mannucci, Pier Mannuccio. ·Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantua, Italy. · Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico" and University of Milan, Italy. ·Blood Transfus · Pubmed #27723453.

ABSTRACT: -- No abstract --

14 Editorial Closing In on Treatment for Hemophilia B. 2017

Porteus, Matthew. ·From the Department of Pediatrics, Stanford University School of Medicine, Stanford, CA. ·N Engl J Med · Pubmed #29211662.

ABSTRACT: -- No abstract --

15 Editorial A promising new treatment horizon for haemophilia A. 2017

The Lancet Haematology, ?. · ·Lancet Haematol · Pubmed #28863796.

ABSTRACT: -- No abstract --

16 Editorial A Cure For Hemophilia: the Promise Becomes a Reality. 2016

Herzog, Roland W. · ·Mol Ther · Pubmed #27687132.

ABSTRACT: -- No abstract --

17 Editorial Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?: Reflections on a possible way forward. 2016

Keipert, C / van den Berg, H M / Keller-Stanislawski, B / Hilger, A. ·Hematology and Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany. christine.keipert@pei.de. · University Medical Center Utrecht, Utrecht, The Netherlands. · Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany. · Hematology and Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany. ·Haemophilia · Pubmed #27397094.

ABSTRACT: -- No abstract --

18 Editorial Pioneering therapeutic proteins in hemophilia care through innovative technologies. 2016

Pabinger-Fasching, Ingrid / Négrier, Claude. ·Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Electronic address: Ingrid.pabinger@meduniwien.ac.at. · Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France. Electronic address: claude.negrier@chu-lyon.fr. ·Thromb Res · Pubmed #27288062.

ABSTRACT: -- No abstract --

19 Editorial Haemophilia and low bone mass. Ok, but what about fracture risk? 2016

Anagnostis, P / Karras, S N / Vakalopoulou, S / Terpos, E. ·Second Propedeutic Department of Internal Medicine, Haemophilia Centre of Northern Greece, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. · Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. · Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. ·Haemophilia · Pubmed #26809834.

ABSTRACT: -- No abstract --

20 Editorial Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response. 2015

Herzog, Roland W. · ·Mol Ther · Pubmed #26321180.

ABSTRACT: -- No abstract --

21 Editorial [To implement prophylactic treatment and improve the quality of life in patients with hemophilia in China]. 2015

Yang, Renchi. ·Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China. ·Zhonghua Xue Ye Xue Za Zhi · Pubmed #26304072.

ABSTRACT: -- No abstract --

22 Editorial Transition considerations for extended half-life factor products. 2015

Croteau, S E / Neufeld, E J. ·Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA. ·Haemophilia · Pubmed #25855484.

ABSTRACT: -- No abstract --

23 Editorial Switching haemophilia products and inhibitor risk: a United States' perspective. 2015

Nance, Danielle / Rodgers, George M. ·Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA. ·Eur J Haematol · Pubmed #25800968.

ABSTRACT: -- No abstract --

24 Editorial Haemophilia. 2015

Brody, Herb. · ·Sci Am · Pubmed #25597114.

ABSTRACT: -- No abstract --

25 Editorial Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge? 2013

Liras, Antonio / García-Trenchard, Rebecca. ·Department of Physiology, Biological Sciences School, Complutense University of Madrid, Cell Therapy and Regenerative Medicine Unit, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, 28040, Spain. ·Expert Rev Hematol · Pubmed #24083561.

ABSTRACT: -- No abstract --

Next